Race Executes Key Contract for Israel Phase 2 AML Trial
Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the…
Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
ASX Announcements
Share Price
Latest News
CEO Phil Lynch Talks to the Australian Shareholder Association Podcast
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our…
Race Executes Contract to Commence Phase 2 Extramedullary AML Trial
Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in…
Race appoints Professor Michael Kelso as Principal Scientist
20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of…
Race Oncology May 2021 Investor Update
Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond….
MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Bisantrene Drug Combinations
Race Oncology Limited (“Race”) is pleased to announce a team of researchers, led by Professor…
